MedPath

(LARS) Score Validation of Turkish Language

Completed
Conditions
LARS - Low Anterior Resection Syndrome
Interventions
Procedure: Rectal Resection Patients
Registration Number
NCT05289531
Lead Sponsor
Ankara University
Brief Summary

Long-term bowel dysfunction after resection for rectal cancer, known as low anterior resection syndrome (LARS), is observed in many patients. The LARS score was developed to measure this syndrome and its impact on quality of life in Danish patients. Recently, English and many other language versions have been validated. The aim of this study was to validate the Turkish translation of the LARS score in Turkish patients who have undergone treatment for rectal cancer.

Detailed Description

A total of 326 patients were reviewed and contacted for the study, and 222 (68%) were eligible for the analyses. The association between the LARS score and quality of life and the test-retest reliability were studied. The intraclass correlation coefficient (ICC) was calculated to understand the degree of reliability.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
222
Inclusion Criteria

The inclusion criteria were

  • rectal adenocarcinoma within 15 cm from the anal verge
  • LAR with either PME or TME.
  • Bowel continuity restored for at least 18 months when invited for the study.
Exclusion Criteria

Exclusion criteria included

  • failed R0 surgery,
  • recurrence or dissemination,
  • having intestinal stoma,
  • previous cancer (except minor skin cancers)
  • dementia and inability to speak Turkish (i.e., the need for a translator during treatment).

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
52 patients re-questioned to answer the same questionaire as control groupRectal Resection PatientsThe test-retest reliability of the LARS score was evaluated by asking 52 randomly selected subgroup of eligible patients to repeat the assessment of the LARS score 2 to 4 weeks after their initial response. Agreement between tests for the LARS score category and for each of the five LARS score items is presented as proportions with 95% confidence intervals. We considered it a perfect agreement if the patient ticked the exact same response category at both tests, a moderate agreement if responses differed by one category, while 'no agreement' was applied to patients whose responses differed by two or more categories. The intraclass correlation coefficient was used to evaluate the agreement between the initial test and the retest. The limit of agreements was calculated by using the Bland-Altman method. An ICC between 0.61 and 0.80 is considered strong agreement. A "p value" less than 0.05 was considered significant.
Rectal resection patientsRectal Resection PatientsFour Turkish centers participated in data collection in 2016. The inclusion criteria were rectal adenocarcinoma within 15 cm from the anal verge and LAR with either PME or TME. All patients had bowel continuity restored for at least 18 months when invited for the study. Exclusion criteria included failed R0 surgery, recurrence or dissemination, having intestinal stoma, previous cancer (except minor skin cancers) dementia and inability to speak Turkish (i.e., the need for a translator during treatment). A research assistant at each center identified the consecutive series of eligible patients for each participating consultant surgeon
Primary Outcome Measures
NameTimeMethod
Validity of LARS ScoreFrom Feb 2016 to Feb 2020

The translated questionaire was validated on Turkish speaking patients

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath